Kas teil on kaebus ELi institutsiooni või asutuse kohta?
- Ekspordi PDF-i
- Hangi lehe lühilink
- Jaga seda lehteTwitterFacebookLinkedin
- ENEnglish
Ombudsman inquiry strengthens transparency and objectivity of EMA's assessment of new medicines
Juhtum OI/7/2017/KR - Alguskuupäev: {0} Esmaspäev | 17 juuli 2017 - Otsuse kuupäev: {0} Kolmapäev | 17 juuli 2019 - Asjassepuutuvad institutsioonid Euroopa Ravimiamet (Edasine uurimine ei ole põhjendatud )

26 November 2019 - An Ombudsman inquiry into how the European Medicines Agency (EMA) engages with pharma companies before they apply for market access for their medicines has led to several measures to improve the transparency and objectivity of the process.
Working constructively with the Ombudsman, EMA has agreed to introduce a log of the scientific advice concerning medicines in the market approval process. This advice will be made public once the medicine is allowed to be sold in Europe. EMA has also said that, to the greatest extent possible, the experts that are prominently involved in advising pharmaceutical companies in the pre-market application phase will not be those that draft EMA's evaluation report for a new medicine.
- Ekspordi PDF-i
- Hangi lehe lühilink
- Jaga seda lehteTwitterFacebookLinkedin